Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Edelman, MJ; Wang, X; Hodgson, L; Cheney, RT; Baggstrom, MQ; Sachdev, T; Gajra, A; Bertino, EM; Reckamp, KL; Molina, J; Schiller, J; Mitchell-Edwards, K; Friedman, P; Ritter, J; Milne, G; Stinchcombe, TE; Hahn, O; Vokes, EE

Published Date

  • May 1, 2017

Published In

Volume / Issue

  • 98 / 1

Start / End Page

  • 220 - 221

PubMed ID

  • 28586968

Pubmed Central ID

  • 28586968

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2017.01.038

Language

  • eng

Conference Location

  • United States